ST. Joseph's Hospital, INC.
ST. Joseph's Hospital, INC. was paid $70.65M by Medicaid between Jan 2018 and Dec 2024, across 561 billing codes. Its largest line is 99283, emergency room visit (moderate) — 22% of everything it billed.
TAMPA, FL 33607
Next to other Psychiatric Hospital Unit providers in Florida
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Paid by month
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 238,868 | $2.65M | |
| 2019 | 696,998 | $10.04M | |
| 2020 | 580,637 | $8.08M | |
| 2021 | 645,515 | $13.34M | |
| 2022 | 574,716 | $18.64M | |
| 2023 | 259,999 | $11.43M | |
| 2024incomplete | 113,788 | $6.48M |
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 22% | 158,449 | 145,502 | $15.45M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 15% | 138,151 | 115,795 | $10.76M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 5.3% | 54,233 | 43,563 | $3.76M |
| 80053 | Comprehensive metabolic panel | 4.3% | 133,770 | 109,073 | $3.02M |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | 3.9% | 39,686 | 37,971 | $2.76M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.7% | 14,919 | 12,674 | $1.89M |
| 70450 | Computed tomography, head or brain; without contrast material | 2.6% | 24,119 | 19,079 | $1.83M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.6% | 22,708 | 21,474 | $1.83M |
| G0257 | Unscheduled or emergency dialysis treatment for an esrd patient in a hospital outpatient department that is not certified as an esrd facility | 2.4% | 7,243 | 1,491 | $1.72M |
| 80048 | Basic metabolic panel (calcium, ionized) | 2.3% | 71,730 | 49,739 | $1.64M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 2.0% | 17,503 | 4,766 | $1.40M |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 1.6% | 24,814 | 20,556 | $1.15M |
549 more codes
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | 1.4% | 13,048 | $1.01M |
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | 1.3% | 2,415 | $917K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 1.3% | 13,022 | $889K |
| 41899 | Unlisted procedure, dentoalveolar structures | 1.2% | 2,251 | $834K |
| G0378 | Hospital observation service, per hour | 1.2% | 73,977 | $826K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.2% | 19,583 | $823K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 4,683 | $676K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 28,730 | $665K |
| 36415 | Collection of venous blood by venipuncture | <1% | 203,957 | $658K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 6,430 | $655K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 8,034 | $600K |
| 81025 | <1% | 52,893 | $592K | |
| 59899 | <1% | 2,866 | $516K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 4,510 | $487K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 9,509 | $423K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 3,951 | $412K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 2,109 | $381K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 3,228 | $372K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 1,884 | $369K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 6,471 | $347K |
| 82948 | <1% | 66,970 | $311K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 44,483 | $301K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 1,541 | $294K |
| 81003 | <1% | 86,073 | $284K | |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 1,324 | $281K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 7,898 | $281K |
| 90935 | Hemodialysis procedure with single evaluation by a physician | <1% | 321 | $266K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 6,947 | $257K |
| 44970 | <1% | 242 | $241K | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 1,734 | $240K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 5,734 | $237K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 37,004 | $235K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 20,122 | $215K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 3,857 | $213K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 7,515 | $195K |
| 87631 | <1% | 2,949 | $184K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 8,046 | $179K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 1,568 | $166K |
| 70498 | <1% | 1,061 | $160K | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 18,868 | $159K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 201,131 | $157K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 23,910 | $156K |
| 97162 | <1% | 2,594 | $155K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 10,053 | $154K |
| 93017 | <1% | 3,034 | $132K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 3,264 | $123K |
| 96415 | <1% | 2,939 | $122K | |
| G0330 | Facility services for dental rehabilitation procedure(s) performed on a patient who requires monitored anesthesia (e.g., general, intravenous sedation (monitored anesthesia care) and use of an operating room | <1% | 149 | $120K |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 223 | $104K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 18,657 | $101K |
| Q4081 | Injection, epoetin alfa, 100 units (for esrd on dialysis) | <1% | 3,763 | $99K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 14,573 | $94K |
| 84702 | <1% | 9,115 | $93K | |
| 70491 | <1% | 600 | $92K | |
| 96367 | <1% | 1,569 | $91K | |
| 97161 | <1% | 2,253 | $90K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 31,680 | $90K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 5,055 | $82K |
| 71045 | Radiologic examination, chest; single view | <1% | 39,455 | $81K |
| 36430 | <1% | 1,632 | $79K | |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 1,027 | $76K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 61,535 | $72K |
| 75574 | <1% | 1,135 | $71K | |
| 72131 | <1% | 1,563 | $67K | |
| 87536 | <1% | 2,982 | $66K | |
| 87070 | <1% | 4,207 | $59K | |
| 73564 | <1% | 4,819 | $56K | |
| 92526 | <1% | 2,694 | $56K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 11,782 | $55K |
| 54161 | <1% | 250 | $53K | |
| 73130 | <1% | 3,744 | $50K | |
| A9270 | Non-covered item or service | <1% | 13,311 | $49K |
| 84484 | <1% | 46,796 | $47K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 832 | $46K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 44,811 | $45K |
| 73110 | <1% | 2,957 | $45K | |
| 74018 | <1% | 5,882 | $45K | |
| 74019 | <1% | 5,871 | $45K | |
| 76377 | <1% | 680 | $44K | |
| 73610 | <1% | 4,094 | $44K | |
| 76825 | <1% | 764 | $43K | |
| 73630 | <1% | 4,491 | $43K | |
| 88304 | <1% | 1,976 | $41K | |
| 93976 | <1% | 4,256 | $41K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 1,959 | $40K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 6,036 | $39K |
| 74230 | <1% | 455 | $39K | |
| 0100U | <1% | 2,077 | $38K | |
| 70486 | <1% | 1,844 | $37K | |
| 97802 | <1% | 329 | $37K | |
| 80076 | <1% | 7,758 | $37K | |
| 82657 | <1% | 1,919 | $36K | |
| 76770 | <1% | 2,114 | $35K | |
| 93970 | <1% | 3,215 | $35K | |
| 85610 | <1% | 24,417 | $34K | |
| 10061 | <1% | 897 | $34K | |
| 95782 | <1% | 75 | $33K | |
| P9040 | Red blood cells, leukocytes reduced, irradiated, each unit | <1% | 633 | $32K |
| 80061 | Lipid panel | <1% | 27,177 | $32K |
| 73030 | <1% | 4,161 | $32K | |
| 87641 | <1% | 4,676 | $32K | |
| 01922 | <1% | 1,987 | $31K | |
| 86003 | <1% | 3,206 | $31K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 6,317 | $30K |
| 73140 | <1% | 1,020 | $30K | |
| 95716 | <1% | 322 | $30K | |
| 93971 | <1% | 2,419 | $30K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 15,427 | $30K |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | <1% | 3,574 | $29K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 1,712 | $29K |
| 36591 | <1% | 2,512 | $28K | |
| C1769 | Guide wire | <1% | 3,341 | $28K |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 11,948 | $27K |
| 49083 | <1% | 149 | $26K | |
| 83880 | <1% | 12,420 | $25K | |
| 86850 | <1% | 6,861 | $25K | |
| 70250 | <1% | 395 | $24K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 1,617 | $24K |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 8,407 | $23K |
| 82805 | <1% | 3,970 | $23K | |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | <1% | 194 | $22K |
| 92610 | <1% | 713 | $22K | |
| 73080 | <1% | 2,127 | $22K | |
| 83735 | <1% | 17,451 | $22K | |
| 95816 | <1% | 699 | $22K | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 17,661 | $22K |
| 82728 | <1% | 8,090 | $21K | |
| 87081 | <1% | 3,497 | $21K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 26,974 | $20K |
| 47562 | <1% | 13 | $20K | |
| 42820 | Tonsillectomy and adenoidectomy; younger than age 12 | <1% | 123 | $19K |
| 76801 | <1% | 6,233 | $19K | |
| 87480 | <1% | 6,888 | $18K | |
| Q0163 | Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen | <1% | 2,369 | $18K |
| 73590 | <1% | 2,157 | $17K | |
| 88341 | <1% | 959 | $17K | |
| 81001 | <1% | 22,117 | $17K | |
| 70496 | <1% | 1,004 | $16K | |
| 73090 | <1% | 2,434 | $16K | |
| 83516 | <1% | 2,003 | $15K | |
| 80069 | <1% | 3,820 | $15K | |
| 85660 | <1% | 1,588 | $15K | |
| J1815 | Injection, insulin, per 5 units | <1% | 9,234 | $15K |
| 86140 | <1% | 17,002 | $15K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 7,230 | $14K |
| 82274 | <1% | 1,093 | $14K | |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 2,531 | $14K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 775 | $14K |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 9,887 | $14K |
| 12001 | <1% | 1,631 | $14K | |
| 89050 | <1% | 556 | $13K | |
| 95819 | <1% | 596 | $13K | |
| 88173 | <1% | 278 | $13K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 11,786 | $13K |
| 95951 | <1% | 173 | $13K | |
| 72100 | <1% | 4,333 | $13K | |
| 83655 | <1% | 3,149 | $13K | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 531 | $13K |
| 86364 | <1% | 1,193 | $13K | |
| 97165 | <1% | 352 | $13K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 6,011 | $12K |
| 86900 | <1% | 11,672 | $12K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 17,031 | $12K |
| 87427 | <1% | 1,391 | $12K | |
| 87077 | <1% | 12,815 | $12K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 11,281 | $12K |
| 80074 | <1% | 1,569 | $12K | |
| 85027 | <1% | 16,673 | $12K | |
| 88342 | <1% | 1,871 | $12K | |
| 81229 | <1% | 435 | $12K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 28,284 | $12K |
| 85730 | <1% | 10,404 | $12K | |
| 97597 | <1% | 464 | $11K | |
| 12011 | <1% | 1,951 | $11K | |
| 87186 | <1% | 10,579 | $11K | |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 880 | $11K |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 3,321 | $11K |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 9,287 | $11K |
| 73560 | <1% | 859 | $11K | |
| 85014 | <1% | 4,904 | $11K | |
| 84703 | <1% | 6,941 | $11K | |
| 76010 | <1% | 223 | $11K | |
| P9045 | Infusion, albumin (human), 5%, 250 ml | <1% | 685 | $11K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 18,603 | $11K |
| 12002 | <1% | 1,007 | $10K | |
| 83690 | <1% | 27,080 | $10K | |
| 83970 | <1% | 2,265 | $10K | |
| 77076 | <1% | 334 | $10K | |
| J3490 | Unclassified drugs | <1% | 1,387 | $10K |
| 49465 | <1% | 359 | $10K | |
| 86901 | <1% | 11,671 | $10K | |
| 92588 | <1% | 96 | $10K | |
| 73502 | <1% | 1,954 | $10K | |
| 86008 | <1% | 928 | $9K | |
| 76870 | <1% | 793 | $9K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 357 | $9K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 3,100 | $9K |
| 87040 | <1% | 8,348 | $9K | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 7,524 | $9K |
| 73070 | <1% | 73 | $8K | |
| 29125 | <1% | 2,119 | $8K | |
| 84145 | <1% | 6,062 | $8K | |
| 87640 | <1% | 1,927 | $8K | |
| 86923 | <1% | 2,212 | $8K | |
| 71101 | <1% | 936 | $7K | |
| 85380 | <1% | 5,867 | $7K | |
| 76830 | Ultrasound, transvaginal | <1% | 3,905 | $7K |
| 70360 | <1% | 871 | $7K | |
| 86359 | <1% | 3,124 | $7K | |
| 82247 | <1% | 1,481 | $7K | |
| 85018 | <1% | 3,511 | $7K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 12,577 | $7K |
| 82330 | <1% | 3,077 | $7K | |
| 86480 | <1% | 1,690 | $7K | |
| 83021 | <1% | 1,152 | $6K | |
| 83993 | <1% | 820 | $6K | |
| 78264 | <1% | 44 | $6K | |
| 83605 | <1% | 5,218 | $6K | |
| 73060 | <1% | 1,039 | $6K | |
| 97163 | <1% | 72 | $6K | |
| 82607 | <1% | 7,689 | $6K | |
| 96409 | <1% | 694 | $6K | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 2,548 | $6K |
| 86780 | <1% | 1,436 | $6K | |
| 82785 | <1% | 3,726 | $6K | |
| 72072 | <1% | 1,559 | $6K | |
| 84480 | <1% | 1,675 | $6K | |
| 87506 | <1% | 463 | $6K | |
| 82150 | <1% | 1,578 | $5K | |
| 82378 | <1% | 1,049 | $5K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 3,986 | $5K |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 197 | $5K |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | <1% | 199 | $5K |
| 84439 | <1% | 13,122 | $5K | |
| 47563 | <1% | 12 | $5K | |
| 85045 | <1% | 3,895 | $5K | |
| 93880 | <1% | 925 | $5K | |
| 87510 | <1% | 6,888 | $5K | |
| 87340 | <1% | 2,271 | $5K | |
| 72170 | <1% | 1,381 | $5K | |
| 72040 | <1% | 1,106 | $5K | |
| 87660 | <1% | 6,947 | $5K | |
| 29515 | <1% | 1,047 | $5K | |
| L4350 | Ankle control orthosis, stirrup style, rigid, includes any type interface (e.g., pneumatic, gel), prefabricated, off-the-shelf | <1% | 208 | $5K |
| 86038 | <1% | 1,635 | $5K | |
| 97116 | <1% | 978 | $5K | |
| 88312 | <1% | 3,678 | $5K | |
| 83540 | <1% | 7,925 | $5K | |
| C8929 | Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, complete, with spectral doppler echocardiography, and with color flow doppler echocardiography | <1% | 233 | $5K |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 1,973 | $5K |
| 82670 | <1% | 297 | $4K | |
| 71250 | <1% | 211 | $4K | |
| 82784 | <1% | 3,229 | $4K | |
| 82550 | <1% | 4,409 | $4K | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 7,693 | $4K |
| 99151 | <1% | 837 | $4K | |
| 73552 | <1% | 1,346 | $4K | |
| 74022 | <1% | 944 | $4K | |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 49 | $4K |
| 85576 | <1% | 896 | $4K | |
| 0240U | <1% | 580 | $4K | |
| 29530 | <1% | 860 | $4K | |
| 87493 | <1% | 789 | $4K | |
| 86258 | <1% | 303 | $4K | |
| 84481 | <1% | 1,443 | $4K | |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 1,825 | $3K |
| 90715 | <1% | 3,367 | $3K | |
| 80164 | <1% | 2,048 | $3K | |
| 93356 | <1% | 1,228 | $3K | |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | <1% | 2,075 | $3K |
| 84156 | <1% | 2,001 | $3K | |
| 82803 | <1% | 231 | $3K | |
| 76376 | <1% | 1,312 | $3K | |
| 84100 | <1% | 5,400 | $3K | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 384 | $3K |
| G0123 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, screening by cytotechnologist under physician supervision | <1% | 712 | $3K |
| 82270 | <1% | 329 | $3K | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 6,400 | $3K |
| 88185 | <1% | 67 | $3K | |
| 86665 | <1% | 639 | $3K | |
| 84132 | <1% | 2,268 | $3K | |
| 83550 | <1% | 4,751 | $3K | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 362 | $3K |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 1,861 | $3K |
| 86592 | <1% | 1,149 | $3K | |
| 84403 | <1% | 1,253 | $3K | |
| 00170 | Anesthesia for intraoral procedures, including biopsy | <1% | 2,956 | $3K |
| 51798 | <1% | 868 | $3K | |
| 78226 | <1% | 15 | $3K | |
| 87205 | <1% | 4,544 | $3K | |
| 86360 | <1% | 3,122 | $3K | |
| P9603 | Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated miles actually travelled | <1% | 6,548 | $3K |
| 99152 | <1% | 903 | $3K | |
| 86356 | <1% | 3,119 | $2K | |
| 85652 | <1% | 12,362 | $2K | |
| 73523 | <1% | 263 | $2K | |
| 82105 | <1% | 723 | $2K | |
| 83615 | <1% | 2,989 | $2K | |
| 84550 | <1% | 2,094 | $2K | |
| 86308 | <1% | 1,052 | $2K | |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 2,540 | $2K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 3,345 | $2K |
| 72128 | <1% | 371 | $2K | |
| 87209 | <1% | 727 | $2K | |
| J1453 | Injection, fosaprepitant, 1 mg | <1% | 17 | $2K |
| 82077 | <1% | 1,024 | $2K | |
| 80197 | <1% | 150 | $2K | |
| 84295 | <1% | 1,447 | $2K | |
| 10060 | <1% | 133 | $2K | |
| 86803 | <1% | 998 | $2K | |
| 84153 | <1% | 1,280 | $2K | |
| 87338 | <1% | 631 | $2K | |
| 87075 | <1% | 1,870 | $2K | |
| 73660 | <1% | 68 | $2K | |
| 82140 | <1% | 1,717 | $2K | |
| 84146 | <1% | 248 | $2K | |
| 72050 | <1% | 339 | $2K | |
| 86769 | <1% | 338 | $2K | |
| 92579 | <1% | 31 | $2K | |
| J1953 | Injection, levetiracetam, 10 mg | <1% | 1,104 | $2K |
| 73000 | <1% | 82 | $2K | |
| 92523 | <1% | 14 | $2K | |
| 12013 | <1% | 153 | $2K | |
| 93458 | <1% | 21 | $2K | |
| 82746 | <1% | 5,070 | $2K | |
| C1751 | Catheter, infusion, inserted peripherally, centrally or midline (other than hemodialysis) | <1% | 14 | $2K |
| 96417 | <1% | 202 | $2K | |
| G0108 | Diabetes outpatient self-management training services, individual, per 30 minutes | <1% | 59 | $2K |
| 0399T | <1% | 480 | $2K | |
| 87015 | <1% | 1,512 | $1K | |
| 99153 | Mod sedat endo service >5yrs | <1% | 1,546 | $1K |
| G0471 | Collection of venous blood by venipuncture or urine sample by catheterization from an individual in a skilled nursing facility (snf) or by a laboratory on behalf of a home health agency (hha) | <1% | 2,873 | $1K |
| 43762 | <1% | 149 | $1K | |
| 97803 | <1% | 12 | $1K | |
| 94770 | <1% | 102 | $1K | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 2,224 | $1K |
| 87486 | <1% | 3,273 | $1K | |
| 87581 | <1% | 3,274 | $1K | |
| 84305 | <1% | 217 | $1K | |
| 93303 | Transthoracic echocardiography for congenital cardiac anomalies, follow-up or limited study | <1% | 129 | $1K |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 2,088 | $1K |
| J0692 | Injection, cefepime hydrochloride, 500 mg | <1% | 1,049 | $1K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 2,001 | $1K |
| 86902 | <1% | 314 | $1K | |
| 82248 | <1% | 2,257 | $1K | |
| 82043 | <1% | 3,780 | $1K | |
| 77001 | <1% | 119 | $1K | |
| 83520 | <1% | 237 | $1K | |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 1,682 | $1K |
| 94660 | <1% | 24 | $1K | |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 1,162 | $1K |
| 92550 | <1% | 310 | $1K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 14,769 | $1K |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 2,208 | $1K |
| 95700 | <1% | 579 | $1K | |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 2,355 | $1K |
| 92585 | <1% | 28 | $1K | |
| 92587 | <1% | 26 | $1K | |
| 74240 | <1% | 29 | $991.45 | |
| 29130 | <1% | 360 | $968.62 | |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 1,314 | $947.78 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 723 | $908.90 |
| 59025 | Fetal non-stress test | <1% | 12 | $901.48 |
| 97166 | <1% | 34 | $900.26 | |
| 00731 | <1% | 2,752 | $896.41 | |
| 87045 | <1% | 1,380 | $896.36 | |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | <1% | 2,194 | $894.90 |
| J1720 | Injection, hydrocortisone sodium succinate, up to 100 mg | <1% | 1,250 | $887.62 |
| 95715 | <1% | 37 | $885.86 | |
| 73700 | <1% | 24 | $865.43 | |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | <1% | 348 | $842.59 |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 1,262 | $810.45 |
| 83519 | <1% | 330 | $809.04 | |
| 86160 | <1% | 348 | $795.16 | |
| 84436 | <1% | 2,506 | $787.64 | |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 466 | $776.08 |
| 95957 | <1% | 188 | $747.31 | |
| J0561 | Injection, penicillin g benzathine, 100,000 units | <1% | 523 | $740.20 |
| 62270 | <1% | 94 | $737.98 | |
| 85245 | <1% | 31 | $724.60 | |
| 92611 | <1% | 329 | $707.30 | |
| 87102 | <1% | 214 | $673.26 | |
| 84144 | <1% | 113 | $666.31 | |
| 85347 | <1% | 498 | $661.57 | |
| 36416 | <1% | 130 | $653.21 | |
| 81243 | <1% | 227 | $646.74 | |
| 00635 | <1% | 67 | $604.09 | |
| 87328 | <1% | 1,433 | $603.84 | |
| 89051 | <1% | 19 | $599.72 | |
| 94760 | <1% | 51 | $590.19 | |
| 82375 | <1% | 819 | $576.44 | |
| 83050 | <1% | 816 | $576.44 | |
| G0328 | Colorectal cancer screening; fecal occult blood test, immunoassay, 1-3 simultaneous | <1% | 185 | $575.09 |
| J0461 | Injection, atropine sulfate, 0.01 mg | <1% | 1,614 | $546.27 |
| 73620 | <1% | 34 | $546.26 | |
| J0744 | Injection, ciprofloxacin for intravenous infusion, 200 mg | <1% | 40 | $529.22 |
| 0042T | <1% | 75 | $528.47 | |
| 96376 | <1% | 1,462 | $525.66 | |
| 82947 | <1% | 358 | $503.20 | |
| 87400 | <1% | 189 | $502.91 | |
| 70210 | <1% | 66 | $495.86 | |
| J0610 | Injection, calcium gluconate (fresenius kabi), per 10 ml | <1% | 483 | $486.76 |
| 87329 | <1% | 1,421 | $482.52 | |
| 83525 | <1% | 997 | $476.80 | |
| 81376 | <1% | 57 | $472.87 | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 529 | $436.72 |
| 88313 | <1% | 555 | $420.12 | |
| M0239 | Intravenous infusion, bamlanivimab-xxxx, includes infusion and post administration monitoring | <1% | 120 | $415.62 |
| 82656 | <1% | 46 | $412.17 | |
| 82653 | <1% | 42 | $411.13 | |
| 72110 | <1% | 46 | $405.22 | |
| 82533 | <1% | 121 | $362.07 | |
| 82945 | <1% | 33 | $359.29 | |
| 86376 | <1% | 1,456 | $331.90 | |
| 86800 | <1% | 482 | $302.71 | |
| 93315 | <1% | 13 | $302.60 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 299 | $299.44 |
| 82570 | <1% | 2,438 | $281.40 | |
| 86431 | <1% | 959 | $276.54 | |
| 83001 | <1% | 360 | $256.26 | |
| 86200 | <1% | 46 | $244.72 | |
| 83013 | <1% | 17 | $234.53 | |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 13 | $232.74 |
| 87430 | <1% | 442 | $217.90 | |
| C1725 | Catheter, transluminal angioplasty, non-laser (may include guidance, infusion/perfusion capability) | <1% | 126 | $215.27 |
| 83721 | <1% | 259 | $208.79 | |
| 83002 | <1% | 247 | $202.11 | |
| 82139 | <1% | 155 | $201.64 | |
| 82950 | <1% | 146 | $190.38 | |
| 0352U | <1% | 139 | $180.92 | |
| 86255 | <1% | 1,812 | $178.56 | |
| 73600 | <1% | 35 | $175.18 | |
| 69200 | <1% | 53 | $166.44 | |
| 87481 | <1% | 319 | $160.58 | |
| 86762 | <1% | 73 | $159.22 | |
| 86706 | <1% | 254 | $158.13 | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 16 | $157.14 |
| 00813 | <1% | 1,147 | $154.99 | |
| 84466 | <1% | 14 | $149.44 | |
| M0222 | Intravenous injection, bebtelovimab, includes injection and post administration monitoring | <1% | 19 | $142.13 |
| 83020 | <1% | 1,153 | $139.32 | |
| 84402 | <1% | 373 | $138.87 | |
| 88108 | <1% | 400 | $137.11 | |
| 87449 | <1% | 1,467 | $126.38 | |
| 90686 | <1% | 1,153 | $125.53 | |
| 76937 | <1% | 118 | $123.05 | |
| 84165 | <1% | 151 | $119.27 | |
| 73562 | <1% | 194 | $116.08 | |
| 86039 | <1% | 304 | $115.10 | |
| 00811 | <1% | 301 | $110.16 | |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 860 | $108.62 |
| Q0244 | Injection, casirivimab and imdevimab, 1200 mg | <1% | 73 | $107.60 |
| 87116 | <1% | 63 | $100.09 | |
| 00300 | <1% | 57 | $96.34 | |
| 86225 | <1% | 141 | $92.93 | |
| 82379 | <1% | 186 | $90.74 | |
| 85379 | <1% | 516 | $86.66 | |
| 87206 | <1% | 62 | $86.17 | |
| 86317 | <1% | 208 | $83.56 | |
| 82652 | <1% | 204 | $72.52 | |
| 85240 | <1% | 93 | $71.50 | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 106 | $67.96 |
| 82565 | <1% | 85 | $66.92 | |
| 86709 | <1% | 243 | $64.69 | |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 1,264 | $52.99 |
| 87046 | <1% | 1,382 | $52.51 | |
| 86235 | <1% | 42 | $50.37 | |
| 85384 | <1% | 72 | $49.74 | |
| 88184 | <1% | 69 | $48.87 | |
| G0008 | Administration of influenza virus vaccine | <1% | 371 | $47.11 |
| 69210 | <1% | 67 | $46.61 | |
| 86663 | <1% | 618 | $43.10 | |
| 82977 | <1% | 1,062 | $40.30 | |
| 82010 | <1% | 381 | $38.19 | |
| 86256 | <1% | 670 | $38.18 | |
| 00320 | <1% | 14 | $37.59 | |
| 84479 | <1% | 193 | $32.38 | |
| 86664 | <1% | 618 | $27.33 | |
| 84134 | <1% | 25 | $26.39 | |
| J0500 | Injection, dicyclomine hcl, up to 20 mg | <1% | 949 | $26.05 |
| J3360 | Injection, diazepam, up to 5 mg | <1% | 113 | $25.11 |
| 87177 | <1% | 701 | $24.80 | |
| 29105 | <1% | 258 | $24.58 | |
| 00920 | <1% | 289 | $22.46 | |
| 80177 | <1% | 94 | $20.46 | |
| 88307 | <1% | 32 | $15.19 | |
| 81382 | <1% | 57 | $13.95 | |
| 82787 | <1% | 24 | $13.70 | |
| 86334 | <1% | 46 | $10.47 | |
| 86696 | <1% | 29 | $9.91 | |
| J0456 | Injection, azithromycin, 500 mg | <1% | 213 | $8.78 |
| J7510 | Prednisolone oral, per 5 mg | <1% | 1,268 | $7.99 |
| 00840 | <1% | 485 | $7.29 | |
| 85246 | <1% | 30 | $6.85 | |
| 86695 | <1% | 29 | $6.60 | |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | <1% | 208 | $4.63 |
| 80178 | <1% | 14 | $4.58 | |
| 82103 | <1% | 33 | $3.62 | |
| 86231 | <1% | 34 | $3.36 | |
| 82705 | <1% | 28 | $3.31 | |
| J1790 | Injection, droperidol, up to 5 mg | <1% | 503 | $2.14 |
| 00790 | <1% | 246 | $2.00 | |
| A9537 | Technetium tc-99m mebrofenin, diagnostic, per study dose, up to 15 millicuries | <1% | 133 | $1.76 |
| 82465 | <1% | 125 | $1.57 | |
| J9370 | Vincristine sulfate, 1 mg | <1% | 343 | $1.49 |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 78 | $1.24 |
| 51702 | <1% | 18 | $1.18 | |
| 88300 | <1% | 15 | $0.87 | |
| C1758 | Catheter, ureteral | <1% | 55 | $0.31 |
| 84157 | <1% | 36 | $0.29 | |
| 87529 | <1% | 13 | $0.29 | |
| 94761 | <1% | 14 | $0.29 | |
| 83918 | 0% | 32 | $0.00 | |
| 93567 | 0% | 40 | $0.00 | |
| 86774 | 0% | 12 | $0.00 | |
| J0153 | Injection, adenosine, 1 mg (not to be used to report any adenosine phosphate compounds) | 0% | 12 | $0.00 |
| 00812 | 0% | 13 | $0.00 | |
| Q9950 | Injection, sulfur hexafluoride lipid microspheres, per ml | 0% | 180 | $0.00 |
| J1580 | Injection, garamycin, gentamicin, up to 80 mg | 0% | 36 | $0.00 |
| 24640 | 0% | 53 | $0.00 | |
| 0353U | 0% | 314 | $0.00 | |
| 88230 | 0% | 44 | $0.00 | |
| 00140 | 0% | 36 | $0.00 | |
| 01920 | 0% | 15 | $0.00 | |
| 92950 | 0% | 15 | $0.00 | |
| 88262 | 0% | 63 | $0.00 | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | 0% | 14 | $0.00 |
| J0295 | Injection, ampicillin sodium/sulbactam sodium, per 1.5 gm | 0% | 49 | $0.00 |
| 90791 | Psychiatric diagnostic evaluation | 0% | 219 | $0.00 |
| 93568 | 0% | 15 | $0.00 | |
| C1760 | Closure device, vascular (implantable/insertable) | 0% | 17 | $0.00 |
| 73100 | 0% | 13 | $0.00 | |
| A9541 | Technetium tc-99m sulfur colloid, diagnostic, per study dose, up to 20 millicuries | 0% | 30 | $0.00 |
| 90670 | 0% | 14 | $0.00 | |
| J9260 | Injection, methotrexate sodium, 50 mg | 0% | 38 | $0.00 |
| 86922 | 0% | 21 | $0.00 | |
| 88311 | 0% | 17 | $0.00 | |
| 84210 | 0% | 80 | $0.00 | |
| 83935 | 0% | 40 | $0.00 | |
| 87425 | 0% | 101 | $0.00 | |
| 00126 | 0% | 26 | $0.00 | |
| 01400 | 0% | 48 | $0.00 | |
| C2617 | Stent, non-coronary, temporary, without delivery system | 0% | 32 | $0.00 |
| J7999 | Compounded drug, not otherwise classified | 0% | 36 | $0.00 |
| 01480 | 0% | 40 | $0.00 | |
| 96411 | 0% | 51 | $0.00 | |
| 93531 | 0% | 70 | $0.00 | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | 0% | 20 | $0.00 |
| G0009 | Administration of pneumococcal vaccine | 0% | 14 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
Who's on the registration
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.